Collectively, our results are consistent with the expected outcomes of an activated NF-κB signaling pathway, and provide evidence that miR-1180 contributes to cisplatin-induced resistance in HCC by targeting this pathway. This evidence concerns the gene NFKB1 and hepatocellular carcinoma.